natgillin/translations-raw huggingface dataset:
Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood.
Občasni neželeni učinki (pojavijo se pri največ 1 od 100 bolnikov) okužbe sečil, okužbe zgornjih dihal (npr. bolečine v grlu, vneti sinusi, prehlad), pomanjkanje rdečih krvničk (anemija), visoka raven kalija, težave z uspavanjem, občutek žalosti (depresija), omedlevica (sinkopa), vrtoglavica, počasen srčni utrip (bradikardija), nizek krvni tlak (hipotenzija) pri osebah, ki se zdravijo zaradi visokega krvnega tlaka, omotica pri vstajanju (ortostatska hipotenzija), zasoplost, kašelj, trebušne bolečine, driska, nelagodje v trebuhu, napenjanje, bruhanje, srbež, povečano znojenje, medikamentni izpuščaj, bolečine v hrbtu, mišični krči, mišična bolečina (mialgija), ledvična okvara, tudi akutna ledvična odpoved, bolečina v prsnem košu, občutek oslabelosti in zvišana raven kreatinina v krvi.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON OF THE MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) - WITHOUT BLUE BOX - 80 mg
VMESNA OVOJNINA PRI SKUPNEM PAKIRANJU PO 360 TABLET (4 PAKIRANJA PO 90 x 1 TABLETO) - BREZ MODREGA OKENCA - 80 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON OF THE MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) - WITHOUT BLUE BOX - 40 mg
VMESNA OVOJNINA PRI SKUPNEM PAKIRANJU PO 360 TABLET (4 PAKIRANJA PO 90 x 1 TABLETO) - BREZ MODREGA OKENCA - 40 mg
What Micardis looks like and contents of the pack Micardis 40 mg tablets are white, oblong-shaped, and engraved with the code number '51H' on one side and the company logo on the other side.
Tablete Micardis 40 mg so bele, podolgovate tablete z vtisnjeno kodno številko 51H na eni in logom podjetja na drugi strani.
What Micardis looks like and contents of the pack Micardis 80 mg tablets are white, oblong-shaped and engraved with the code number '52H' on one side and the company logo on the other side.
Tablete Micardis 80 mg so bele, podolgovate tablete z vtisnjeno kodno številko 52H na eni in logom podjetja na drugi strani.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER LABEL ON MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) BUNDLEDINCLUDING THE BLUE BOX - 80 mg
ZUNANJE OZNAČEVANJE PRI SKUPNEM PAKIRANJU PO 360 TABLET (4 PAKIRANJA PO 90 x 1 TABLETO) - Z MODRIM OKENCEM - 80 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER LABEL ON MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) BUNDLEDINCLUDING THE BLUE BOX - 40 mg
ZUNANJE OZNAČEVANJE PRI SKUPNEM PAKIRANJU PO 360 TABLET (4 PAKIRANJA PO 90 x 1 TABLETO) - Z MODRIM OKENCEM - 40 mg
Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.
Zdravila ali terapevtske skupine zdravil, ki lahko povzročijo hiperkaliemijo so nadomestki soli s kalijem, diuretiki, ki zadržujejo kalij; zaviralci ACE,
White round tablets of 2.5 mm engraved with the code number '50H' on one side and the company logo on the other side.
Micardis 20 mg tablete Bele, 2,55 mm okrogle tablete z vtisnjeno kodno številko 50H na eni in logom podjetja na drugi strani.
NAME OF THE MEDICINAL PRODUCT Micardis 20 mg tablets
IME ZDRAVILA Micardis 20 mg tablete Micardis 40 mg tablete Micardis 80 mg tablete
- are 65 years of age or older.
- ste stari 65 let ali več.
Date of first authorisation: 18 December 2013 Date of latest renewal: 20 November 2018
Datum prve odobritve: 18. december 2013 Datum zadnjega podaljšanja: 20. november 2018
The absolute bioavailability is 75%.
Absolutna biološka uporabnost je 75 %.
EXP {MM-YYYY}
EXP{MM-LLLL}
Do this even if there are no signs of discomfort.
To storite tudi, če ni znakov nelagodja.
A risk to the breastfeeding child cannot be excluded.
Tveganje za dojenega otroka ne moremo izključiti.
Treatment should be continued for at least 6 months after you feel well again.
Zdravljenje je potrebno nadaljevati vsaj še 6 mesecev po tem, ko se spet dobro počutite.
Take one tablet with a glass of water.
Vzemite eno tableto s kozarcem vode.
Impact on human fertility has not been observed so far.
Vpliv na plodnost pri človeku doslej še ni bil opažen.
Pack of 1 glass bottle.
Pakiranje z 1 steklenico.
Tell your doctor if you are taking any of the following medicines:
Povejte svojemu zdravniku, če jemljete katerokoli izmed naslednjih zdravil:
* Based on post-marketing cases
* Na podlagi primerov po začetku trženja.
For information on undesirable effects, see section 4.8.
Za informacije o neželenih učinkih glejte poglavje 4.8.
- have low sodium level in the blood.
- imate nizko raven natrija v krvi.
Component of a multipack, can't be sold separately.
Sestavni del večkratnega pakiranja; se ne sme prodajati ločeno.
The mean volume of distribution (Vss) is 2,600 L, indicating extensive extravascular distribution.
Povprečen volumen porazdelitve (VSS) je 2.600 L, kar kaže na obsežno ekstravaskularno porazdelitev.
In the majority of instances, such complications began immediately or soon (<24 hours) after delivery.
V večini primerov do zapletov pride takoj ali kmalu (< 24 ur) po rojstvu.
The requirements for submission of periodic safety reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahteve za predložitev posodobljenih poročil o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in vseh nadaljnjih posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
The list is based on information from clinical trials and post-marketing experience.
Seznam temelji na podatkih iz kliničnih preskušanj in izkušenj po začetku trženja.
- have had mania.
- ste kdaj imeli manijo.
Thoughts of suicide and worsening of your depression
Misli na samomor in poslabšanje depresije
Doses of 5 to 15 mg showed no difference to placebo.
Odmerki od 5 do 15 mg ne kažejo nobene razlike od placeba.
Medical follow-up in a specialised environment is recommended.
Priporočljivo je zdravniško spremljanje v specializirani enoti.
Abnormal dreams
Nenormalne sanje
Brintellix should not be used during pregnancy unless the doctor says it is absolutely necessary.
Zdravila Brintellix ne smete uporabljati med nosečnostjo, razen če zdravnik pravi, da je to nujno potrebno.
- if you are allergic to vortioxetine or any of the other ingredients of this medicine (listed in section 6).
- če ste alergični na vortioksetin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
In the majority of cases, no symptoms or mild symptoms were reported.
V večini primerov niso poročali o simptomih ali so poročali o blagih simptomih.
Taking these medicines together with Brintellix may increase the risk of serotonin syndrome.
Jemanje teh zdravil skupaj z zdravilom Brintellix lahko poveča tveganje za serotoninski sindrom.
[outer carton only] PC:
[samo zunanja škatla] PC:
In 1 case, anaphylactic shock was reported.
Pri 1 primeru so poročali o anafilaktičnem šoku.
The bottle must be turned completely upside down.
Steklenico je treba popolnoma obrniti navzdol.
Target organ toxicity was restricted to kidneys (rats) and liver (mice and rats).
Toksičnost za ciljne organe je bila omejena na ledvice (podgane) in jetra (miši in podgane).
Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events).
Depresija je povezana z večjim tveganjem za pojav samomorilnih misli, samopoškodovanja in samomorilnosti (s samomorom povezani dogodki).
Vortioxetine is highly bound to plasma proteins (98 to 99%) and the binding appears to be independent of vortioxetine plasma concentrations.
Vortioksetin je močno vezan na beljakovine v plazmi (98 do 99 %) in zdi se, da je vezava neodvisna od koncentracije vortioksetina v plazmi.
Side effects listed below have been reported in the following frequencies.
Spodaj naštete neželene učinke so poročali po naslednji pogostnosti:
Patients should be monitored for the emergence of signs and symptoms of SS or NMS (see sections 4.3 and 4.5).
Bolnike je treba spremljati glede možnih znakov in simptomov SS ali NMS (glejte poglavji 4.3 in 4.5).
In the dedicated study in elderly, vortioxetine was also effective in these patients.
V namenski študiji pri starejših bolnikih je bil vortioksetin tudi učinkovit pri teh bolnikih.
After the depressive symptoms resolve, treatment for at least 6 months is recommended for consolidation of the antidepressive response.
Po odpravi depresivnih simptomov je priporočljivo nadaljevati z zdravljenjem vsaj še 6 mesecev, da se utrdi antidepresivni učinek.
The efficacy of vortioxetine increased with increasing dose.
Učinkovitost vortioksetina se povečuje s povečanjem odmerka.
The safety and efficacy of Brintellix in children and adolescents aged less than 18 years have not been established.
Varnost in učinkovitost zdravila Brintellix pri otrocih in mladostnikih, mlajših od 18 let, nista dokazani.
Continue to take Brintellix even if it takes some time before you feel any improvement in your condition.
Nadaljujte z jemanjem zdravila Brintellix, četudi bo trajalo nekaj časa, preden boste občutili izboljšanje svojega stanja.
It is expected that the ingredients of Brintellix will pass into breast milk.
Pričakovati je, da bodo sestavine zdravila Brintellix prehajale v materino mleko.
Approximately 2/3 of the inactive vortioxetine metabolites are excreted in the urine and approximately 1/3 in the faeces.
Približno 2/3 neaktivnih presnovkov vortioksetina se izloči z urinom in približno 1/3 z blatom.
Management of overdose should consist of treating clinical symptoms and relevant monitoring.
Obravnavanje prevelikega odmerjanja naj vključuje zdravljenje kliničnih simptomov in relevantno spremljanje.
Most cases were a combination of airway and skin symptoms.
Večina primerov je bila kombinacija simptomov dihal in kože.
Have the container and any remaining tablets available.
Imejte vsebnik in preostale tablete pri sebi.
However, the precise contribution of the individual targets to the observed pharmacodynamic profile remains unclear and caution should be applied when extrapolating animal data directly to man.
Vendar pa natančen prispevek posameznih ciljnih receptorjev v opazovanem farmakodinamičnem profilu ostaja nejasen in potrebna je previdnost pri ekstrapolaciji podatkov iz živali neposredno na človeka.
These symptoms could be due to either discontinuation effects or excess serotonergic activity.
Ti simptomi so lahko posledica odtegnitvenih učinkov ali presežne serotonergične aktivnosti.
If this occurs, treatment with vortioxetine should be discontinued immediately and symptomatic treatment should be initiated.
Če se to zgodi, je treba zdravljenje z vortioksetinom takoj prekiniti in uvesti simptomatsko zdravljenje.
Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome (NMS)
Serotoninski sindrom (SS) ali nevroleptični maligni sindrom (NMS)
Brintellix should only be administered to pregnant women if the expected benefits outweigh the potential risk to the foetus.
Nosečnice lahko Brintellix prejmejo le, če so pričakovane koristi večje od možnega tveganja za plod.
Pruritus, including pruritus generalised
Srbenje, vključno z generaliziranim srbenjem
Similar effects were seen in the rabbit at sub-therapeutic exposure.
Podobne vplive so opazili pri kuncih pri subterapevtski izpostavljenosti.
The mechanism of action of vortioxetine is thought to be related to its direct modulation of serotonergic receptor activity and inhibition of the serotonin (5-HT) transporter.
Domneva se, da je mehanizem delovanja vortioksetina povezan z njegovo neposredno modulacijo aktivnosti serotonergičnega receptorja in inhibicijo prenašalca serotonina (5-HT).
Although no studies have investigated the association of PPHN with vortioxetine treatment, this potential risk cannot be ruled out taking into account the related mechanism of action (increase in serotonin concentrations).
Čeprav nobena študija ni preiskovala povezanosti med PPHN in zdravljenjem z vortioksetinom, tega potencialnega tveganja ni mogoče izključiti, saj je potrebno upoštevati, da gre za podoben način delovanja (povečanje koncentracij serotonina).
Do not stop taking Brintellix without talking with your doctor.
Ne prenehajte jemati zdravila Brintellix, ne da bi se posvetovali s svojim zdravnikom.
In a thorough QTc study in healthy subjects at doses up to 40 mg daily, no potential for the prolongation of the QTc interval was observed.
Pri temeljiti študiji intervala QTc pri zdravih osebah pri odmerkih do 40 mg na dan niso opazili potenciala za podaljšanje intervala QTc.
Based on results from conventional 2-year carcinogenicity studies in mice or rats, vortioxetine is not considered to pose a risk of carcinogenicity in humans.
Na osnovi rezultatov 2-letnih konvencionalnih študij kancerogenosti pri miših ali podganah vortioksetin ne predstavlja tveganja za rakotvornost pri ljudeh.
- medicines known to cause low sodium level.
- zdravila za katera je znano, da povzročajo nizko raven natrija.
Brintellix is not recommended in children and adolescents under 18 years due to lack of information for this age group.
Zdravila Brintellix ne priporočajo otrokom in mladostnikom, mlajšim od 18 let, zaradi pomanjkanja podatkov za to starostno skupino.
This multimodal activity is considered responsible for the antidepressant and anxiolytic-like effects and the improvement of cognitive function, learning and memory observed with vortioxetine in animal studies.
Domneva se, da je ta multimodalna aktivnost odgovorna za učinke, podobne učinkom antidepresivov in anksiolitikov, in za izboljšanje kognitivne funkcije, učenja in spomina, ki je bilo opaženo pri vortioksetinu v študijah na živalih.
However, alcohol intake is not advisable during antidepressant treatment.
Vendar pa vnos alkohola med zdravljenjem z antidepresivom ni priporočljiv.
The maintenance of antidepressant efficacy was demonstrated in a relapse-prevention study.
Vzdrževanje antidepresivne učinkovitosti so dokazali v študiji o preprečevanju relapsov.
Gastrointestinal adverse reactions, such as nausea, occurred more frequently in women than men.
Gastrointestinalni neželeni učinki, kot je navzea, so pogostejši pri ženskah kot pri moških.
Steady-state plasma concentrations are achieved in approximately 2 weeks.
Koncentracija v plazmi v stanju dinamičnega ravnovesja je dosežena v približno 2 tednih.
- bupropion (a medicine to treat depression also used to wean from smoking).
- bupropion (zdravilo za zdravljenje depresije; uporablja se tudi za odvračanje od kajenja).
These included salivation (rat and dog), pupil dilatation (dog), and two incidences of convulsions in dogs in the general toxicity study programme.
Med njimi so bili slinjenje (podgane in psi), dilatacija zenice (psi) in dve incidenci konvulzije pri psih v programu študije splošne toksičnosti.
Vortioxetine is a poor P-gp substrate and inhibitor.
Vortioksetin je slab substrat in inhibitor P-gp.
Vortioxetine is slowly, but well absorbed after oral administration and the peak plasma concentration is reached within 7 to 11 hours.
Vortioksetin se po peroralnem jemanju počasi, vendar dobro absorbira in največja koncentracija v plazmi je dosežena v roku od 7 do 11 ur.
Environmental risk assessment studies have shown that vortioxetine has the potential to be pesistent, bioaccumulative and toxic to the environment (risk to fish).
V študijah za ocenjevanje tveganja za okolje so pokazali, da je vortioksetin potencialno obstojen, bioakumulativen in toksičen za okolje (tveganje za ribe).
In humans, two positron emission tomography (PET) studies have been conducted using 5-HT transporter ligands (11C-MADAM or 11C-DASB) to quantify the 5-HT transporter occupancy in the brain across different dose levels.
Pri ljudeh so opravili dve študiji s pozitronsko emisijsko tomografijo (PET), z uporabo ligandov prenašalca 5-HT (11C-MADAM ali 11C-DASB), za kvantifikacijo zasedenosti prenašalca 5-HT v možganih pri različnih odmerkih.
In juvenile toxicity studies in rats, all vortioxetine treatment-related findings were consistent with those noted in adult animals.
V študijah toksičnosti pri mladih podganah so bile vse ugotovitve v povezavi z zdravljenjem vortioksetina skladne s tistimi, navedene za odrasle živali.
Caution should therefore be exercised (see section 5.2).
Zato je potrebna previdnost (glejte poglavje 5.2).
The drops can be mixed with water, juice or other non-alcoholic drinks.
Kapljice se lahko mešajo z vodo, s pomarančnim sokom ali z drugimi brezalkoholnimi pijačami.
Furthermore, vortioxetine, in the dose range of 5-20 mg/day, demonstrated efficacy on the broad range of depressive symptoms (assessed by improvement in all MADRS single-item scores).
Poleg tega je vortioksetin, v razponu odmerkov od 5 do 20 mg/dan, dokazal učinkovitost pri najrazličnejših depresivnih simptomih (ocenjeno z izboljšanjem vseh točk v posamičnih postavkah po lestvici MADRS).
Please tell your doctor if you are taking any of the medicines above, since your doctor needs to know if you already are at risk for seizures.
Povejte svojemu zdravniku, če jemljete katero od zgoraj navedenih zdravil, saj mora vaš zdravnik vedeti, če pri vas že obstaja tveganje za epileptične napade.
Turn the bottle completely upside down.
Steklenico obrnite navpično navzdol.
In clinical studies, sexual dysfunction was assessed using the Arizona Sexual Experience Scale (ASEX).
V kliničnih študijah je bila spolna disfunkcija ocenjena z uporabo arizonske lestvice spolne izkušnje (ASEX - Arizona Sexual Experience Scale).
Brintellix has no or negligible influence on the ability to drive and use machines.
Zdravilo Brintellix nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Fits are a potential risk with medicines used to treat depression.
Krči so možno tveganje pri zdravilih, ki se uporabljajo za zdravljenje depresije.
The most frequently reported symptoms were nausea and vomiting.
Simptoma, o katerih so poročali najpogosteje, sta bila navzea in bruhanje.
Vortioxetine was not genotoxic in a standard battery of in vitro and in vivo tests.
Vortioksetin ni bil genotoksičen v seriji standardnih in vitro in in vivo testov.
There was no clinically relevant difference to placebo in the incidence or nature of the discontinuation symptoms after either short-term (6-12 weeks) or long-term (24-64 weeks) treatment with vortioxetine.
Klinično pomembnih razlik s placebom v incidenci ali naravi odtegnitvenih simptomov ni bilo, niti po kratkoročnem (6-12 tednov) niti dolgoročnem (24-64 tednov) zdravljenju z vortioksetinom.
Data on the use of Brintellix in elderly patients with major depressive episodes are limited.
Podatki o uporabi zdravila Brintellix pri starejših bolnikih z epizodami velike depresije so omejeni.
Patients (and caregivers of patients) should be alerted to the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
Bolnike (in skrbnike bolnikov) je treba opozoriti, da morajo biti pozorni na kakršnokoli klinično poslabšanje, pojav samomorilnega vedenja, misli na samomor in pojav neobičajnih vedenjskih sprememb, ter da se morajo v primeru, da se pojavijo takšni simptomi, nemudoma posvetovati z zdravnikom.
The mean 5-HT transporter occupancy in the raphe nuclei was approximately 50% at 5 mg/day, 65% at 10 mg/day and increased to above 80% at 20 mg/day.
Povprečna zasedenost prenašalca 5-HT v jedrih raphe je bila približno 50 % pri odmerku 5 mg/dan, 65 % pri odmerku 10 mg/dan in se je povečala nad 80 % pri odmerku 20 mg/dan.
However, the 20 mg dose of vortioxetine was associated with an increase in sexual dysfunction (TESD)(see section 5.1) .
Vendar pa je bil odmerek 20 mg vortioksetina povezan s povišano pojavnostjo spolne disfunkcije (TESD - Treatment-Emergent Sexual Dysfunction) (glejte poglavje 5.1).
Class effect
Razredni učinek
No effect of food on the pharmacokinetics was observed (see section 4.2).
Niso opazili nobenega učinka hrane na farmakokinetiko (glejte poglavje 4.2).
If no drops come out, the bottle can be tapped lightly to start the flow.
Če nobena kapljica ne izteče, se lahko narahlo potapka po steklenici, da se začne iztekanje.
In general, the observed side effects were mild to moderate and occurred within the first two weeks of treatment.
Na splošno so bili opaženi neželeni učinki blagi do zmerni in so se pojavili v prvih dveh tednih zdravljenja.
Nonclinical data indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the 5-HT transporter, leading to modulation of neurotransmission in several systems, including predominantly the serotonin but probably also the norepinephrine, dopamine, histamine, acetylcholine, GABA and glutamate systems.
Neklinični podatki kažejo, da je vortioksetin antagonist receptorjev 5-HT3, 5-HT7 in 5-HT1D, delni antagonist receptorja 5-HT1B, agonist receptorja 5-HT1A in inhibitor prenašalca 5-HT, kar vodi do modulacije nevrotransmisije v več sistemih, vključno predvsem s serotoninskim, verjetno pa tudi z noradrenalinskim, dopaminskim, histaminskim in acetilholinskim, GABA in glutaminskim sistemom.
Make sure your midwife and/or doctor know you are on Brintellix.
Poskrbite, da babica oziroma zdravnik vesta, da se zdravite z zdravilom Brintellix.
There are limited data from the use of vortioxetine in pregnant women.
Podatki o uporabi vortioksetina pri nosečnicah so omejeni.
In clinical short- and long-term placebo-controlled studies, potential discontinuation symptoms were systematically evaluated after abrupt treatment cessation of vortioxetine.
V kratko- in dolgoročnih, placebom nadzorovanih kliničnih študijah so bili možni odtegnitveni simptomi sistematično ovrednoteni po nenadnem prenehanju zdravljenja z vortioksetinom.
Potential for vortioxetine to affect other medicinal products
Možnost vpliva vortioksetina na druga zdravila
The pharmacokinetics are linear and time independent in the dose range studied (2.5 to 60 mg/day).
Farmakokinetika je linearna in časovno neodvisna v preučevanem razponu odmerkov (2,5 do 60 mg/dan).
Vortioxetine did not increase the incidence of insomnia or somnolence relative to placebo.
Vortioksetin ni povečal incidence nespečnosti ali zaspanosti v primerjavi s placebom.
Nausea was usually mild or moderate and occurred within the first two weeks of treatment.
Neželeni učinki so bili običajno blagi ali zmerni in so se pojavljali v prvih dveh tednih zdravljenja.
This was supported by clinical relevance as demonstrated by the proportions of responders and remitters and the improvement in the Clinical Global Impression - Global Improvement (CGI-I) score.
To je bilo podprto s kliničnim pomenom, kar so dokazali z deležem odzivnih bolnikov in bolnikov v remisiji in izboljšanjem ocene po lestvici CGI-I (Clinical Global Impression - Global Impovement).
If no drops come out, tap the bottle lightly to start the flow.
Če nobena kapljica ne izteče, narahlo potapkajte po steklenici, da sprožite iztekanje.